Ono Pharmaceutical Co., Ltd. (4528N.MX)
| Previous close | 341.69 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 310.06 x N/A |
| Day's range | 341.69 - 341.69 |
| 52-week range | 341.69 - 341.69 |
| Volume | |
| Avg. volume | 25 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 14.24 |
| EPS (TTM) | 23.99 |
| Earnings date | 29 Jul 2024 - 02 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals
ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH, Chief Executive Officer: Steven L. Hoerter, "Deciphera") today announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer follow
PR NewswireOno Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that in order to accelerate the open innovation, it has increased its investment pool from US$100 million to US$200 million to continue strategic investment in Ono Venture Investment Fund I, L.P. ("OVI FI"), which was established as a corporate venture capital fund in CA, USA in May 2020.
